Loading
A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance is a phase 2 interventional study registered as NCT07285057 by Icahn School of Medicine at Mount Sinai, with 120 participants planned, started 2026-02-10 and due to reach its primary completion in 2027-05-01. Interventions recorded: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18. Conditions recorded: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma.
Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, very low and low risk, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/